Fanconi syndrome and chronic kidney disease in paroxysmal nocturnal hemoglobinuria: effect of eculizumab therapy
Éric Moumas(Inserm), Guy Touchard(Centre Hospitalier Universitaire de Poitiers), Nathalie Quellard(Université de Poitiers), Edouard Randriamalala, Éstelle Desport(Centre Hospitalier Universitaire de Poitiers), Sébastien Delbès(Université de Poitiers), Frank Bridoux(Université de Poitiers), Brigitte Dreyfus, Fannie Leroy, S. Belmouaz(Université de Poitiers)
Cited by 11
Related Papers
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases
|Kidney International|2021|809
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group
|Nature Reviews Nephrology|2018|544
Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant
|Blood|2012|543
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
|New England Journal of Medicine|2007|520